@article{oai:nagoya.repo.nii.ac.jp:02001662, author = {Oie, Yumi and Itoh, Yoshiyuki and Kawamura, Mariko and Takase, Yuuki and Murao, Takayuki and Ishihara, Shunichi and Nomoto, Yoshihito and Hirasawa, Naoki and Asano, Akiko and Yamakawa, Kouji and Ito, Junji and Kinoshita, Fumie and Naganawa, Shinji}, issue = {4}, journal = {Nagoya Journal of Medical Science}, month = {Nov}, note = {The Tokai Study Group for Therapeutic Radiology and Oncology (TOSTRO) started managing T1 glottic cancer using 2.25 Gy/fraction radiotherapy in 2011. The aim was to evaluate the local control (LC) rate and toxicity with 2.25-Gy radiotherapy in clinical practice and identify prognostic factors.The eligibility criteria were T1 glottic squamous cell carcinoma patients with age ≥20 years, treated with 2.25 Gy/fraction without chemotherapy between 2011 and 2017. LC rates were evaluated based on age, performance status, sex, T-category, tumor type (ulcerative or non-ulcerative), presence of anterior commissure invasion, tumor size, X-ray beam energy, and overall treatment time. Acute and late adverse events were evaluated using CTCAE version 4.0. A total of 202 patients were enrolled. The median follow-up period was 34.2 months. The 2- and 4-year LC rates were 93.8% and 93.1%, respectively. There was a significant difference in the LC rate between non-ulcerative type and ulcerative type (95.2% vs. 74.1% at 2 years, 94.4% vs. 74.1% at 4 years; p = 0.01). On univariate analysis, only tumor type was significantly correlated with a poor LC rate (hazard ratio 4.3; 95% confidence interval 1.2–15.4; p = 0.03). Acute grade 3 adverse events occurred in 17 patients. However, no late adverse events of grade 3 or higher have occurred to date. T1 glottic cancer treatment outcomes using hypofractionated radiotherapy with 2.25 Gy/fraction in clinical practice were comparable to previously reported results. However, ulcerative type tumor was associated with a poor LC rate.}, pages = {811--825}, title = {Poor local control of ulcerative T1 glottic cancer treated with 2.25-Gy per fraction radiotherapy}, volume = {83}, year = {2021} }